---
layout: post
title: "Determination That SEMPREX-D (Acrivastine and Pseudoephedrine Hydrochloride) Capsules, 8 Milligrams and 60 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
date: 2026-02-04 21:49:26 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-18813
original_published: 2025-09-29 00:00:00 +0000
significance: 8.00
---

# Determination That SEMPREX-D (Acrivastine and Pseudoephedrine Hydrochloride) Capsules, 8 Milligrams and 60 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness

**Published:** February 04, 2026 21:49 UTC
**Source:** Federal Register
**Original Published:** September 29, 2025 00:00 UTC
**Document Number:** 2025-18813

## Summary

The Food and Drug Administration (FDA or Agency) has determined that SEMPREX-D (acrivastine and pseudoephedrine hydrochloride) capsules, 8 milligrams (mg) and 60 mg, was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for acrivastine and pseudoephedrine hydrochloride capsules, 8 mg and 60 mg, if all other legal and regulatory requirements are met.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/09/29/2025-18813/determination-that-semprex-d-acrivastine-and-pseudoephedrine-hydrochloride-capsules-8-milligrams-and)
- API: https://www.federalregister.gov/api/v1/documents/2025-18813

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
